Hidradenitis suppurativa represents a chronic, debilitating inflammatory condition that damages the follicular unit and surrounding intertriginous tissues. Clinicians increasingly recognize that hidradenitis suppurativa disease progression causes irreversible structural scarring, sinus tract formation, and profound physical impairment. Historically, practitioners lacked a unified, standardized definition to characterize how and when this disease advances. A newly proposed multidimensional consensus framework now synthesizes current clinical evidence to map progression dynamics, risk determinants, and intervention windows.

The Multidimensional Framework: Three Core Blocks

The updated framework organizes disease progression into three overarching blocks that encompass six distinct dimensions. First, the objective severity block evaluates structural escalation through Hurley stage transitions and dynamic inflammatory shifts measured by the International Hidradenitis Suppurativa Severity Score System. Consequently, this block captures both acute inflammatory flare intensity and fixed tissue damage over time.

Second, the anatomical extension block examines disease spread. This dimension tracks both intraregional progression across a single fold and extraregional dissemination to distant intertriginous sites. Therefore, clinicians can clearly identify when localized nodules generalize into regional or widespread systemic disease.

Third, the cumulative disease burden block evaluates secondary structural complications, such as lymphedema, contractures, and squamous cell carcinoma. Furthermore, it incorporates patient-reported outcomes to quantify chronic pain, psychological distress, and impaired functional status. Together, these blocks harmonize clinical assessment directly with European guidelines for step-up biologic and surgical escalation.

Epidemiology and Dynamics of Longitudinal Progression

Available longitudinal studies demonstrate that disease progression rates vary significantly depending on the clinical care setting. Specifically, tertiary academic referral centers report progression rates of approximately 37% over a two-year observation period when using rigorous clinical and ultrasonographic evaluations. In contrast, self-reported community-based registries demonstrate substantially lower progression figures due to diagnostic delays and recall biases.

Moreover, progression does not follow an identical linear timeline in every affected individual. While some patients maintain low-grade inflammation for decades, others experience rapid structural collapse and tunnel interconnectivity within months of disease onset. Accordingly, specialized dermatological centers must track disease dynamics proactively to anticipate architectural damage before irreversible scarring occurs.

Risk Factors Driving Hidradenitis Suppurativa Disease Progression

Epidemiological data reveal several key risk factors that reliably predict disease escalation across demographic, lifestyle, and comorbidity domains. Notably, early age of symptom onset correlates strongly with aggressive, refractory disease trajectories. In addition, active cigarette smoking and high pack-year exposure dramatically accelerate tissue destruction and perpetuate treatment resistance.

Concurrently, systemic comorbidities heavily influence the risk of clinical deterioration. Patients with coexisting inflammatory bowel disease, Down syndrome, or recurrent pilonidal sinus disease exhibit marked susceptibility to rapid anatomical spread. Clinicians must also monitor elevated inflammatory biomarkers, including C-reactive protein and systemic neutrophil counts, because these laboratory markers reflect ongoing, unchecked systemic inflammation.

Phenotypic and Genotypic Architecture of Progression

Clinical phenotype frameworks identify high-risk patient subgroups that warrant intensive monitoring. In particular, male patients with active tobacco dependence, severe concomitant acne conglobata, and extensive lower-body involvement face the highest risk of rapid structural progression. These individuals frequently develop interconnected, fibrotic fistulae across the gluteal and perineal regions.

Simultaneously, complex genetic mechanisms govern these distinct phenotypic presentations, with estimated heritability reaching 77%. For example, pathogenic loss-of-function variants in gamma-secretase and Notch signaling pathways drive classical follicular occlusion and extensive tract formation. Conversely, distinct autoinflammatory syndromes linked to inflammasome dysregulation—including PASH, PAPASH, and SAPHO—generate severe, ulcerating systemic phenotypes that require targeted anti-inflammatory biologic therapies.

Ultrasound and the Subclinical Window of Opportunity

High-frequency Doppler ultrasonography has transformed modern staging by unmasking deep pathology invisible during standard physical examination. Consequently, routine clinical exams frequently underestimate disease severity and delay appropriate intervention. Ultrasound imaging reliably detects subclinical microtunnels, occult fluid collections, and deep dermal pseudocysts long before skin surface changes appear.

Most importantly, sonography identifies the actively inflamed, non-draining tunnel. This specific structural finding represents a critical within-lesion window of opportunity where medical therapies can abort irreversible architectural damage. Therefore, integrating ultrasound allows dermatologists to escalate targeted medical therapy before fibrotic tract maturation necessitates radical surgical excision.

Systemic Consequences and Clinical Management Imperatives

Unchecked disease progression extends far beyond cutaneous boundaries. Persistent systemic inflammation contributes directly to premature atherosclerosis, metabolic syndrome, and elevated cardiovascular morbidity. Furthermore, chronic suppuration and visible disfigurement produce profound psychological morbidity, culminating in high rates of depression, social isolation, and occupational disability.

Because structural damage is largely irreversible, timely intervention is an urgent clinical mandate. Although disease modification through early biologic initiation remains an evolving clinical paradigm, early aggressive therapy prevents cumulative organ damage. Dermatologists and primary physicians must adopt this multidimensional framework to intervene swiftly, optimize multimodal biologic-surgical protocols, and preserve long-term quality of life.

How does the new framework define disease progression?

The framework defines progression across three blocks: objective severity, anatomical extension, and cumulative burden. These blocks incorporate Hurley stage transitions, dynamic score changes, anatomical spreading, and secondary complications. By monitoring these dimensions simultaneously, clinicians can identify advancing tissue damage and escalate systemic or surgical therapies before irreversible scarring occurs.

What role does high-frequency ultrasound play in monitoring?

High-frequency ultrasound detects occult anatomical changes that physical examination cannot identify. It readily visualizes deep inflammatory collections, fibrotic tracts, and subclinical microtunnels. Most crucially, ultrasound identifies inflamed, non-draining tunnels. This unique window of opportunity enables clinicians to introduce targeted medical therapy before tunnels mature into permanent, scarred structures.

Which patient populations face the highest progression risk?

Patients with early-onset symptoms, extensive tobacco use, and lower-body distribution face the greatest risk of structural advancement. Furthermore, coexisting conditions such as inflammatory bowel disease, Down syndrome, and pilonidal disease amplify this risk. Identifying these high-risk clinical profiles enables dermatologists to initiate aggressive biologic therapy and smoking cessation early in the disease course.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or treatment options. Clinicians must exercise their independent clinical judgment when applying information to specific clinical scenarios. Refer to the latest local and national guidelines for clinical practice.

References

1. Molina-Leyva A et al. Disease progression in hidradenitis suppurativa: A multidimensional framework. J Eur Acad Dermatol Venereol. 2026 Sep 13. doi: 10.1111/jdv.70717. PMID: 42732549.


2. Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, et al. International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e496-e499.


3. Wortsman X. Update on the role of color Doppler ultrasound in hidradenitis suppurativa: a game-changer. Dermatol Clin. 2024 Nov;42(4):451-464.